Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Correction

Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Authors: Weiwei Huang, Chenxi Wang, Yangkun Shen, Qi Chen, Zhijian Huang, Jian Liu, Xiaoyan Lin, Lili Wang, Fan Wu, Xinhua Chen, Nani Li, Yi Hong, Mulan Chen, Jieyu Li, Chuanzhong Huang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Excerpt

Correction: BMC Cancer 24, 39 (2024) …
Literature
1.
Metadata
Title
Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
Authors
Weiwei Huang
Chenxi Wang
Yangkun Shen
Qi Chen
Zhijian Huang
Jian Liu
Xiaoyan Lin
Lili Wang
Fan Wu
Xinhua Chen
Nani Li
Yi Hong
Mulan Chen
Jieyu Li
Chuanzhong Huang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12150-8

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer

Research

Prognostic marker CD27 and its micro-environmental in multiple myeloma

Research

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Correction

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Research

The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung

Research

Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits